


Terumo India expands interventional cardiology portfolio with launch of FineCross™ M3

07 October 2025 | News

FineCross™ M3 empowers physicians to perform safer percutaneous coronary intervention procedures



Terumo India, the Indian arm of Japan's Terumo Corporation, has announced the launch of FineCross™ M3 Coronary Micro-Guide Catheter in India. The latest-generation catheter raises the bar for percutaneous coronary intervention (PCI), offering cardiologists enhanced crossing ability, guidewire support, and navigability in complex lesions that often hamper procedural success.

With coronary artery disease (CAD) continuing to be the leading cause of death in India, and a rising proportion of patients presenting with complex lesions it highlights the urgent need for advanced interventional tools. Addressing this challenge, FineCross™ M3 equips cardiologists to perform more efficient, predictable, and safer procedures, enhancing both clinical outcomes and procedural confidence.

Commenting on the launch Shishir Agarwal, President and Managing Director, Terumo India said, "Innovation at Terumo India is always guided by enabling physicians to deliver the best possible care to patients. With the launch of FineCross™ M3, we are proud to bring a globally trusted advancement in interventional cardiology to India. This milestone reflects not only our commitment to strengthening cardiovascular care in the country, but also Our Promise "Unwavering commitment to patients" that lies at the heart of everything we do."

FineCross™ M3 integrates Terumo's legacy of engineering excellence with new design enhancements that address real-world challenges in percutaneous coronary intervention (PCI).

Adding perspective on the product's clinical relevance, Nitin Stephen Abel, Senior Director, Terumo Interventional Systems, Terumo India said, "FineCross™ M3 represents more than just a product launch, it reflects our continued focus on advancing cardiovascular care in India in line with Terumo's mission of contributing to society through healthcare. Through globally trusted innovations, we aim to empower physicians in delivering better patient outcomes and create a meaningful impact

where it matters most.”

The launch of FineCross™ M3 adds to Terumo India’s growing portfolio of advanced interventional solutions, further strengthening its role in shaping the future of cardiovascular care in the country.